| Code | CSB-RA011626MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to astegolimab, targeting IL1RL1 (interleukin-1 receptor-like 1), also known as ST2. IL1RL1 functions as a receptor for IL-33 and plays a critical role in type 2 immune responses by activating Th2 cells, mast cells, and innate lymphoid cells. Upon IL-33 binding, IL1RL1 triggers inflammatory signaling cascades that contribute to allergic inflammation, tissue fibrosis, and airway remodeling. Dysregulated IL1RL1/IL-33 signaling has been implicated in chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis, and various inflammatory disorders.
Astegolimab is a clinical-stage therapeutic antibody that blocks IL-33 binding to IL1RL1, thereby inhibiting downstream inflammatory responses. This biosimilar antibody provides researchers with a valuable tool for investigating IL1RL1-mediated pathways in pulmonary diseases, fibrotic conditions, and type 2 inflammation. It supports studies examining the therapeutic potential of IL1RL1 blockade and mechanisms underlying chronic respiratory and inflammatory diseases.
There are currently no reviews for this product.